Business Wire

BentallGreenOak Announces Its Commitment to Achieving Net Zero Emissions by 2050 or Sooner for Its Entire Global Real Estate Portfolio

1.11.2021 08:00:00 EET | Business Wire | Press release

Share

BentallGreenOak (“BGO”) today announced that it is joining the Net Zero Asset Managers initiative, which commits the company to achieving Net Zero greenhouse gas emissions by no later than 2050 for its entire commercial real estate investment portfolio. The firm’s historic track record for successfully reducing and offsetting carbon emissions in the built environment will be instrumental in setting an enhanced course on targets that recognize the need for radical disruption to address the urgent threat of climate change.

By joining the Net Zero Asset Managers initiative, BGO commits to supporting investing aligned with Net Zero emissions by 2050 or sooner. In line with global efforts, including goals established in the Paris Agreement to limit warming by 1.5°C, BGO’s commitment specifically means:

  • BGO will work in partnership with investor clients on their decarbonization goals, consistent with an ambition to reach net zero emissions by 2050 or sooner across all assets under management (AUM).
  • Within one year, BGO will set an interim target for the proportion of assets to be managed in line with the target of Net Zero emissions by 2050 or sooner.
  • BGO will review its interim target at least every five years, increasing the proportion of AUM covered until 100% of assets are included.

“Today’s announcement committing BGO to Net Zero emissions across our global portfolio is within reach in our lifetimes because we have been charting a course for well over a decade to substantially reduce our environmental footprint. Our commitment to environmental stewardship forms part of the fabric of our firm’s culture and the responsibility we share to create a more hopeful future,” said Sonny Kalsi, co-CEO of BentallGreenOak. "BGO’s real estate investment platform is integrally tied to a world-leading ESG program that draws its strength from proprietary tools, technologies, research and information systems to deliver real and measurable outcomes. The positive trajectory of our emissions reductions programs across our managed portfolio will continue to be a compelling part of our offering to institutional investors, and a source of untapped potential that we will continue to pursue as part of our overall growth strategy for the firm.”

To help achieve this goal, BGO has established its own proprietary Global Net Zero Framework which draws on more than a decade of ESG experience and stewardship in commercial real estate. BGO’s Global Net Zero Framework is actively creating a collaborative process between portfolio managers, asset managers, & property managers to design targets for carbon reduction, the boundaries for these targets, full-fledged delivery strategies, and cost forecasting for the duration of the commitment. BGO leaders representing every business across the global enterprise will guide the firm’s commitments through a rigorous planning period that confirms a course of action and then executes the strategies that include action on deep retrofits, lower carbon development projects, renewable energy use and efficiency strategies, adoption of prop-tech innovations, and the procurement of offsets.

“BGO is approaching its Net Zero emissions objective with a structured and credible plan. We are aligning to a growing and certain consensus from the investor community and a wide range of public stakeholders who are looking to responsible real estate asset managers to respond to the climate emergency.” said Anna Murray, Managing Director and Global Head of ESG for BentallGreenOak. “It will be our renewed mission to demonstrate accountability and tangible action on climate change. There is enormous opportunity in front of us that can only be captured through collaborative efforts across our global teams and in alignment with our clients’ objectives.”

BGO’s commitment to Net Zero emissions by 2050 also applies to the firm’s corporate operations. Since 2014, BGO has purchased renewable energy credits (RECs) and quality carbon offsets for its North American operations and will look to further expand carbon neutrality initiatives across its global corporate footprint to meet its 2050 goal.

The Net Zero Asset Managers initiative is a group of international asset managers committed to supporting the goal of net zero greenhouse gas emissions by 2050 or sooner, in line with global efforts to limit warming to 1.5 degrees Celsius; and to supporting investing aligned with net zero emissions by 2050 or sooner.

The initiative is managed globally by six Founding Partner investor networks, namely: Asia Investor Group on Climate Change (AIGCC), CDP, Ceres, Investor Group on Climate Change (IGCC), Institutional Investors Group on Climate Change (IIGCC) and Principles for Responsible Investment (PRI). In turn, the initiative is endorsed by The Investor Agenda, of which the investor networks are all founding partners.

Visit BentallGreenOak’s Sustainable Investing website to learn more about BGO’s Net Zero commitment: www.bentallgreenoak.com/esg

About BentallGreenOak

BentallGreenOak is a leading, global real estate investment management advisor and a globally-recognized provider of real estate services. BentallGreenOak serves the interests of more than 750 institutional clients with approximately $69 billion USD of assets under management (as of June 30, 2021) and expertise in the asset management of office, industrial, multi-residential, retail and hospitality property across the globe. BentallGreenOak has offices in 24 cities across twelve countries with deep, local knowledge, experience, and extensive networks in the regions where we invest in and manage real estate assets on behalf of our clients in primary, secondary and co-investment markets.

BentallGreenOak is a part of SLC Management, which is the alternatives asset management business of Sun Life.

The assets under management shown above includes real estate equity and mortgage investments managed by the BentallGreenOak group of companies and their affiliates, and as of 1Q21, includes certain uncalled capital commitments for discretionary capital until they are legally expired and excludes certain uncalled capital commitments where the investor has complete discretion over investment.

For more information, please visit www.bentallgreenoak.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media

Rahim Ladha
BentallGreenOak
media@bentallgreenoak.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release

Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release

Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release

In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release

The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye